Emerg Infect Dis by Wilson, Brigid M. et al.
Y.D. was supported by research grants from the National  
Institutes of Health (R01AI104895, R21AI123747).
Dr. Li is a visiting researcher at the University of Pittsburgh. His 
research interests include mechanisms of multidrug resistance in 
gram-negative bacteria.
References
  1. Davis MA, Baker KN, Orfe LH, Shah DH, Besser TE, Call DR. 
Discovery of a gene conferring multiple-aminoglycoside resistance 
in Escherichia coli. Antimicrob Agents Chemother. 2010;54:2666–
9. http://dx.doi.org/10.1128/AAC.01743-09
  2. Lee CS, Li JJ, Doi Y. Complete sequence of conjugative IncA/C 
plasmid encoding CMY-2 β-lactamase and RmtE 16S rRNA 
methyltransferase. Antimicrob Agents Chemother. 2015;59:4360–1. 
http://dx.doi.org/10.1128/AAC.00852-15
  3. Xia J, Sun J, Li L, Fang LX, Deng H, Yang RS, et al. First report 
of the IncI1/ST898 conjugative plasmid carrying rmtE2 16S 
rRNA methyltransferase gene in Escherichia coli. Antimicrob 
Agents Chemother. 2015;59:7921–2. http://dx.doi.org/10.1128/
AAC.01235-15
  4. Thomson GK, Snyder JW, McElheny CL, Thomson KS, Doi Y.  
Coproduction of KPC-18 and VIM-1 carbapenemases by  
Enterobacter cloacae: implications for newer β-lactam-β-lactamase 
inhibitor combinations. J Clin Microbiol. 2016;54:791–4.  
http://dx.doi.org/10.1128/JCM.02739-15
  5. Blaak H, Hamidjaja RA, van Hoek AH, de Heer L,  
de Roda Husman AM, Schets FM. Detection of extended-spectrum 
β-lactamase (ESBL)–producing Escherichia coli on flies at  
poultry farms. Appl Environ Microbiol. 2014;80:239–46.  
http://dx.doi.org/10.1128/AEM.02616-13
  6. Baraniak A, Izdebski R, Fiett J, Gawryszewska I, Bojarska K, 
Herda M, et al. NDM-producing Enterobacteriaceae in Poland, 
2012–14: inter-regional outbreak of Klebsiella pneumoniae ST11 
and sporadic cases. J Antimicrob Chemother. 2016;71:85–91. 
http://dx.doi.org/10.1093/jac/dkv282
  7. Yu T, He T, Yao H, Zhang JB, Li XN, Zhang RM, et al. Prevalence 
of 16S rRNA methylase gene rmtB among Escherichia coli isolated 
from bovine mastitis in Ningxia, China. Foodborne Pathog Dis. 
2015;12:770–7. http://dx.doi.org/10.1089/fpd.2015.1983
  8. Rahman M, Prasad KN, Pathak A, Pati BK, Singh A, Ovejero 
CM, et al. RmtC and RmtF 16S rRNA methyltransferase in 
NDM-1–producing Pseudomonas aeruginosa. Emerg Infect Dis. 
2015;21:2059–62. http://dx.doi.org/10.3201/eid2111.150271
Address for correspondence: Yohei Doi, Division of Infectious Diseases, 
University of Pittsburgh School of Medicine, S829 Scaife Hall, 3550 
Terrace St, Pittsburgh, PA 15261, USA; email: yod4@pitt.edu
Carbapenem-Resistant  
Enterobacter cloacae  
in Patients from the US  
Veterans Health  
Administration, 2006–2015
Brigid M. Wilson, Nadim G. El Chakhtoura, 
Sachin Patel, Elie Saade, Curtis J. Donskey, 
Robert A. Bonomo, Federico Perez
Author affiliations: Louis Stokes Cleveland Department of  
Veterans Affairs Medical Center, Cleveland, Ohio, USA  
(B.M. Wilson, N.G. El Chakhtoura, C.J. Donskey, R.A. Bonomo,  
F. Perez); University Hospitals Cleveland Medical Center,  
Cleveland (N.G. El Chakhtoura, S. Patel, E. Saade,  
R.A. Bonomo); Case Western Reserve University School of  
Medicine, Cleveland (C.J. Donskey, R.A. Bonomo, F. Perez) 
DOI: http://dx.doi.org/10.3201/eid2305.162034
We analyzed carbapenem-resistant Enterobacteriaceae 
(CRE) trends among patients from the US Veterans Health 
Administration (VHA). After the emergence of CRE in the 
eastern United States, resistance rates remained stable in 
Klebsiella pneumoniae but increased in Enterobacter cloa-
cae complex, suggesting a “second epidemic.” VHA offers a 
vantage point for monitoring nationwide CRE trends.
Carbapenem-resistant Enterobacteriaceae (CRE) have become a global public health threat. The epidemic of 
CRE began in the early 2000s with an outbreak of carbape-
nem-resistant Klebsiella pneumoniae harboring K. pneu-
moniae carbapenemase (KPC) in the eastern United States. 
Since then, KPC-producing K. pneumoniae have emerged 
in various communities across the country (1). Carbapenem 
resistance also occurs in other Enterobacteriaceae species 
and can be mediated by other enzymes, such as OXA-48 
and metallo-β-lactamases, especially New Delhi metallo-
β-lactamase and Verona integron–encoded metallo-β-
lactamase (1). Carbapenem-resistant Escherichia coli oc-
curs infrequently, but recent outbreaks of KPC-producing 
Enterobacter cloacae raise concerns about the emergence 
of carbapenem resistance in the E. cloacae complex (1–4).
The Veterans Health Administration (VHA) is the larg-
est integrated healthcare system in the United States. Clini-
cal and microbiologic data for the entire VHA network are 
accessible through its informatics platforms (5). We used 
this infrastructure to observe national trends of carbapenem 
resistance and nonsusceptibility in K. pneumoniae and E. 
cloacae complex during the past decade.
We identified 224,651 K. pneumoniae and 71,462 
E. cloacae complex (E. cloacae, E. asburiae, E. kobei, 
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E. hormaechei, E. xiafangensis) isolates from patients hos-
pitalized during 2006–2015. To minimize bias introduced 
by variability in susceptiblity reporting, we excluded iso-
lates obtained within 30 days of another isolate from the 
same patient and isolates from facilities with nonstandard 
reporting, facilitites that identified <30 isolates in a 2-year 
period, and facilities that reported carbapenem susceptibili-
ties for <90% of isolates. After these exclusions, 128,431 
K. pneumoniae and 38,219 E. cloacae complex isolates 
from 140 facilities in 40 states, District of Columbia, and 
Puerto Rico remained for study. We obtained carbapenem 
(i.e., meropenem, imipenem, ertapenem, doripenem) sus-
ceptibility test results (i.e., susceptible, intermediate, or 
resistant) and calculated rates of resistance and nonsuscep-
tibility to any carbapenem over time, looking at 2-year win-
dows and grouping facilities into 10 regions designated by 
the US Department of Health and Human Services (https://
www.hhs.gov/about/agencies/regional-offices/index.html).
Our data capture the chronologic and geographic 
spread of carbapenem-resistant K. pneumoniae and E. cloa-
cae complex within VHA (Figure). Before 2010, carbapen-
em-resistant K. pneumoniae was observed primarily in the 
eastern United States, but by 2014–2015, the rate of car-
bapenem resistance detected in K. pneumoniae was >1% in 
all regions except Regions 8 (South Dakota, North Dakota, 
Montana, Wyoming, Colorado, Utah) and 10 (Washington, 
Oregon, Idaho, Alaska). In 2006–2007, carbapenem-resis-
tant E. cloacae complex also had a focus in the East, but 
in 2008–2009, it was also observed in Region 8. By 2014–
2015, carbapenem-resistant E. cloacae complex was cen-
tered in the Southwest and Pacific Coast. These regions also 
had higher rates of carbapenem-nonsusceptible E. cloacae 
complex, although this phenotype was present in all regions.
The carbapenem-nonsusceptibility rate among K. 
pneumoniae isolates remained at 3%–4% throughout 
2006–2015; however, as with a 2016 study (6), we detected 
a recent decrease in the rate of carbapenem resistance in 
K. pneumoniae in Region 2, which includes New York. In 
contrast, the rates of carbapenem resistance and nonsuscep-
tibility in E. cloacae complex increased nationwide during 
the last decade, reaching >4% nonsusceptibility and 2.5% 
resistance in 2014–2015. Also, the proportion of intermedi-
ate carbapenem-nonsusceptible isolates was higher for E. 
cloacae complex (46%) than K. pneumoniae (9%) isolates.
CRE trends during 2006–2015 in the VHA recapitu-
late the epidemic of carbapenem-resistant K. pneumoniae 
in the United States and indicate that a “second epidemic” 
of carbapenem-resistant E. cloacae complex appears to be 
unfolding. In the United States, the predominant carbape-
nem-resistant K. pneumoniae genotype is sequence type 
(ST) 258, which is associated with Tn4401, a mobile ge-
netic element containing bla
KPC
 (7). In contrast, the genetic 
background of carbapenem-resistant E. cloacae complex 
is not well defined. Analysis of carbapenem-resistant E. 
cloacae from the US Midwest and New York, NY, demon-
strated dissemination of E. cloacae complex ST171 harbor-
ing the bla
KPC-3
 gene (2,3,8). Further analysis demonstrated 
that ST171 was associated with a Tn4401 variant within a 
pBK30683-like plasmid; however, various other plasmids 
in Enterobacter spp. also harbor bla
KPC-3
 (4). Of note, in a 
northeastern US hospital, one third of carbapenem-resistant 
E. cloacae contained carbapenemases and the rest harbored 
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Figure. Geographic and temporal trends of carbapenem nonsusceptibility and resistance in Enterobacteriaceae seen at Veterans 
Health Administration facilities, United States, 2006–2015. A) Dissemination of carbapenem-resistant Klebsiella pneumoniae 
after an initial focus in the eastern United States. B) Nationwide percentage of carbapenem nonsusceptibility and resistance in K. 
pneumoniae. C) Emergence and dissemination (“second epidemic”) of carbapenem-nonsusceptible and -resistant Enterobacter 
cloacae complex. D) Nationwide percentage of carbapenem nonsusceptibility and resistance in E. cloacae complex. Isolates from 
patients in Puerto Rico were not included in the maps. 
cephalosporinases, usually only AmpC (9). Nevertheless, 
we hypothesize that E. cloacae complex contains geno-
types with epidemic potential associated with increasing 
rates of carbapenem resistance observed in the VHA.
The scope of this study did not include molecular char-
acterization, so we could not determine emerging geno-
types or detect outbreaks at individual facilities. Also, non-
uniform susceptibility testing and interpretation throughout 
the VHA may affect reporting of CRE. Although criteria for 
interpretation of carbapenem susceptibility changed during 
the past decade, the revised breakpoints do not appear to 
have a major effect on resistance rates in Klebsiella and En-
terobacter spp., according to other surveillance data (10). 
Despite these limitations, the VHA may serve as a vantage 
point for detecting nationwide trends in antimicrobial drug 
resistance. Integration of susceptibility testing with mo-
lecular characterization at the VHA may help elucidate the 
changing epidemiology of CRE in the United States.
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To determine the potential role of vertical transmission in 
Zika virus expansion, we evaluated larval pools of perorally 
infected Aedes aegypti and Ae. albopictus adult female 
mosquitoes; ≈1/84 larvae tested were Zika virus–posi-
tive; and rates varied among mosquito populations. Thus, 
vertical transmission may play a role in Zika virus spread 
and maintenance.
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